Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Marinus Pharma (NASDAQ:MRNS) and maintained a $28 price target.
June 23, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst reiterates Overweight rating on Marinus Pharma (NASDAQ:MRNS) and maintains a $28 price target.
The reiteration of the Overweight rating and maintenance of the $28 price target by Cantor Fitzgerald analyst Charles Duncan indicates a positive outlook for Marinus Pharma. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100